image
Healthcare - Medical - Devices - NASDAQ - US
$ 0.3442
2.25 %
$ 11.6 M
Market Cap
-0.29
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CODX stock under the worst case scenario is HIDDEN Compared to the current market price of 0.344 USD, Co-Diagnostics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CODX stock under the base case scenario is HIDDEN Compared to the current market price of 0.344 USD, Co-Diagnostics, Inc. is HIDDEN

This DCF valuation model was last updated on Apr, 22, 2025.

The intrinsic value of one CODX stock under the best case scenario is HIDDEN Compared to the current market price of 0.344 USD, Co-Diagnostics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CODX

image
$1.3$1.3$1.2$1.2$1.1$1.1$1.0$1.0$0.9$0.9$0.8$0.8$0.7$0.7$0.6$0.6$0.5$0.5$0.4$0.4$0.3$0.3$0.2$0.2Nov '24Nov '2415 Nov15 NovDec '24Dec '2415 Dec15 DecJan '25Jan '2515 Jan15 JanFeb '25Feb '2515 Feb15 FebMar '25Mar '2515 Mar15 MarApr '25Apr '2515 Apr15 Apr
FINANCIALS
3.92 M REVENUE
-42.53%
-40.1 M OPERATING INCOME
6.15%
-37.6 M NET INCOME
-6.53%
-29.2 M OPERATING CASH FLOW
-32.03%
17.1 M INVESTING CASH FLOW
10.93%
104 K FINANCING CASH FLOW
107.62%
149 K REVENUE
-76.71%
-11.9 M OPERATING INCOME
-16.34%
-11 M NET INCOME
-13.77%
-8.23 M OPERATING CASH FLOW
-13.85%
266 K INVESTING CASH FLOW
-93.62%
104 K FINANCING CASH FLOW
0.00%
Balance Sheet Co-Diagnostics, Inc.
image
Current Assets 32.3 M
Cash & Short-Term Investments 29.7 M
Receivables 133 K
Other Current Assets 2.41 M
Non-Current Assets 31.7 M
Long-Term Investments 0
PP&E 4.88 M
Other Non-Current Assets 26.8 M
46.48 %3.77 %7.62 %41.93 %Total Assets$64.0m
Current Liabilities 7.32 M
Accounts Payable 3.29 M
Short-Term Debt 916 K
Other Current Liabilities 3.11 M
Non-Current Liabilities 2.37 M
Long-Term Debt 1.24 M
Other Non-Current Liabilities 1.14 M
34.00 %9.45 %32.06 %12.76 %11.72 %Total Liabilities$9.7m
EFFICIENCY
Earnings Waterfall Co-Diagnostics, Inc.
image
Revenue 3.92 M
Cost Of Revenue 999 K
Gross Profit 2.92 M
Operating Expenses 43 M
Operating Income -40.1 M
Other Expenses -2.44 M
Net Income -37.6 M
5m5m00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)4m(999k)3m(43m)(40m)2m(38m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
74.48% GROSS MARGIN
74.48%
-1023.75% OPERATING MARGIN
-1023.75%
-961.37% NET MARGIN
-961.37%
-69.30% ROE
-69.30%
-58.81% ROA
-58.81%
-69.69% ROIC
-69.69%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Co-Diagnostics, Inc.
image
50m50m40m40m30m30m20m20m10m10m00(10m)(10m)(20m)(20m)(30m)(30m)20162016201720172018201820192019202020202021202120222022202320232024202420252025
Net Income -37.6 M
Depreciation & Amortization 1.38 M
Capital Expenditures -748 K
Stock-Based Compensation 5.43 M
Change in Working Capital 2.75 M
Others -938 K
Free Cash Flow -29.9 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Co-Diagnostics, Inc.
image
Wall Street analysts predict an average 1-year price target for CODX of $9 , with forecasts ranging from a low of $6 to a high of $12 .
CODX Lowest Price Target Wall Street Target
6 USD 1643.17%
CODX Average Price Target Wall Street Target
9 USD 2514.76%
CODX Highest Price Target Wall Street Target
12 USD 3386.35%
Price
Max Price Target
Min Price Target
Average Price Target
121210108866442200Jun '24Jun '24Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 19
6. Ownership
Insider Ownership Co-Diagnostics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
All You Need to Know About CoDiagnostics (CODX) Rating Upgrade to Buy CoDiagnostics (CODX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 1 month ago
Co-Diagnostics, Inc. (CODX) Reports Q4 Loss, Misses Revenue Estimates Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.36 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.50 per share a year ago. zacks.com - 1 month ago
Co-Diagnostics, Inc. (CODX) Q4 2024 Earnings Call Transcript Co-Diagnostics, Inc. (NASDAQ:CODX ) Q4 2024 Earnings Conference Call March 27, 2025 4:30 PM ET Company Participants Andrew Benson - IR Dwight Egan - CEO Brian Brown - CFO Conference Call Participants Operator Good day, and welcome to the Co-Diagnostics Fourth Quarter and Full Year 2024 Earnings Conference Call. All participants will be in a listen-only mode. seekingalpha.com - 1 month ago
Co-Diagnostics, Inc. Reports Full Year 2024 Financial Results SALT LAKE CITY , March 27, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the fourth quarter and full year ended December 31, 2024. Full Year 2024 Financial Results: Revenue of $3.9 million, which declined from $6.8 million during the prior year primarily due to higher Grant revenue in 2023. prnewswire.com - 1 month ago
Co-Diagnostics, Inc. Announces Fourth Quarter and Full Year 2024 Earnings Release Date and Webcast SALT LAKE CITY , March 13, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its fourth quarter and full year 2024 results on Thursday, March 27, 2025, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. prnewswire.com - 1 month ago
Co-Diagnostics, Inc. Wins Dismissal of Class Action Lawsuit SALT LAKE CITY , March 6, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that on March 4, 2025, the Securities & Governance Litigation Team at BakerHostetler, the legal firm retained to represent the Company, won complete dismissal on summary judgment of a Section 10(b) securities class action that had been pending against the Company in the United States District Court for the District of Utah. See Gelt Trading, Ltd. prnewswire.com - 1 month ago
Co-Diagnostics, Inc. and CoSara to Host HPV and Cancer Symposium on International HPV Day 2025 The symposium exploring advances in cancer prevention and care is set to take place on March 4, International HPV Awareness Day, in Baroda, India SALT LAKE CITY , March 3, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the Company and CoSara Diagnostics Pvt. Ltd. ("CoSara"), the joint venture between Ambalal Sarabhai Enterprises Limited (ASE Group) and Co-Dx, will be hosting a symposium to honor International HPV (human papillomavirus) Awareness Day 2025. prnewswire.com - 2 months ago
Penny Stock Co-Diagnostics Withdraws FDA Application For COVID-19 Test, Plans To Submit Enhanced Version On Friday, Co-Diagnostics, Inc.  CODX withdrew its FDA 510(k) application for its Co-Dx PCR COVID-19 Test on the PCR Pro in favor of submitting an enhanced version of the test for 510(k) clearance. benzinga.com - 2 months ago
Co-Diagnostics, Inc. to Participate at the Nasdaq Live from MarketSite Broadcast at Silicon Slopes 2025 SALT LAKE CITY , Jan. 7, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be participating in Nasdaq's Live from MarketSite broadcast at the Silicon Slopes Summit 2025 on January 14, 2025. Live from MarketSite is Nasdaq's flagship broadcast opportunity, showcasing innovative leaders and disruptive companies in their fields. prnewswire.com - 3 months ago
Co-Diagnostics, Inc. and CoSara Diagnostics to Inaugurate New Oligo Facility New oligonucleotide facility is designed to support "Make in India" initiative by synthesizing Co-Primers® in-house. Attendees of new ribbon-cutting event expected to include representatives from NGOs and government leaders SALT LAKE CITY , Dec. 10, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that the inauguration of CoSara Diagnostics Pvt. prnewswire.com - 4 months ago
Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript Co-Diagnostics, Inc. (NASDAQ:CODX ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations. Dwight Egan - CEO Brian Brown - CFO Conference Call Participants Jade Montgomery - H.C. seekingalpha.com - 5 months ago
Co-Diagnostics, Inc. (CODX) Reports Q3 Loss, Tops Revenue Estimates Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.20 per share a year ago. zacks.com - 5 months ago
8. Profile Summary

Co-Diagnostics, Inc. CODX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 11.6 M
Dividend Yield 0.00%
Description Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Contact 2401 South Foothill Drive, Salt Lake City, UT, 84109 https://www.codiagnostics.com
IPO Date July 12, 2017
Employees 132
Officers Dr. Mayuranki Almaula Ph.D. Senior Vice President of Overseas Operations & Strategic Alliances Mr. Seth Egan Chief Commercialization Officer Mr. David Nielsen Chief Operating Officer Mr. Andrew Benson Head of Investor Relations Mr. Richard David Abbott President Mr. Christopher Thurston Chief Technology Officer Mr. Dwight H. Egan Chairman & Chief Executive Officer